Skip to content
Research Article Open access CC BY 4.0

Atherogenic Diabetic Dyslipidemia

Dheeraj Kapoor, Ruchi Kapoor, Kunal Jhaveri

Asian Journal of Research and Reports in Endocrinology · pp. 158–163 · Published 12 Sep 2022

Abstract

Diabetes is a widely prevalent condition and steadily growing as well. In Indian type 2 diabetic patients have a higher amounts of TG and atherogenic lipid sd-LDL. Atherogenic diabetic dyslipidemia is associated with higher residual CV risk and should be treated with a statin as first-line agent. The tendency to develop insulin resistance is a common result of Asian Indians' body composition and dyslipidemia. Diabetic dyslipidemia (DD) is defined by a mild to marked increase in triglyceride-rich lipoproteins, very low-density lipoprotein-cholesterol (VLDL-C) and VLDL-C remnants, and low HDL levels. Along with lifestyle modifications, statins are considered as first-line therapy for diabetic dyslipidemia. Statins have the ability to reduce LDL-C levels by up to 50%. They might improve TG and HDL-C levels further.

Diabetes dyslipidemia cardiovascular diseases hypertriglyceridemia saroglitazar

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.